Aims  The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results  Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24 h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0–100%), fibrinolysis (18.8%; 0–100%), and no reperfusion therapy (9.0%; 0–75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.5–5.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8–97.5%) for the performance of reperfusion therapy of all patients with STEMI <12 h and 54.4% (region range 37.1–70.1%) for timely reperfusion. Conclusions  The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality.

No abstract

No abstract

Background: Myocardial shape and function can be altered by diabetes alone, without the presence of other risk factors like hypertension, ischemic heart disease and a condition known as diabetic cardiomyopathy (DCM). Diabetes is associated with a wide range of metabolic disturbances, some of which have been linked to the emergence of DCM. Some examples are elevated blood sugar levels, abnormal lipid profiles, an increase in the release of free fatty acids (FFAs), and insulin resistance.Objective: Review of literature about correlation between heart failure and diabetes mellitus. Methods: Heart failure and diabetes mellitus were searched for on Science Direct, Google Scholar, and PubMed. The authors also reviewed the relevant literature, nonetheless, only the most recent or exhaustive analysis was included, covering the time span from September 2010 to November 2022. There are no translation resources available, thus non-English documents are out. Unpublished articles, oral presentations, conference abstracts, and dissertations were not included because they were not considered to be part of major scientific projects. Conclusion:There is a lack of understanding of the molecular underpinnings and pathophysiology of heart failure in diabetic people. The incidence, prevalence, and outlook for heart failure in diabetic individuals have been proven by certain clinical and epidemiologic data. In recent decades, diabetic heart disease has emerged as a major contributor to the mortality rate among diabetics.